Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy.
Saved in:
| Title: | Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy. |
|---|---|
| Authors: | Walle T; Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany. t.walle@dkfz.de.; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany. t.walle@dkfz.de.; German Cancer Consortium (DKTK), Heidelberg, Germany. t.walle@dkfz.de., Bajaj S; Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Kraske JA; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Rösner T; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Cussigh CS; Department of Dermatology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Kälber KA; Department of Dermatology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Müller LJ; Department of Hematology, University Hospital Heidelberg, Heidelberg, Germany., Strobel SB; Department of Dermatology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Burghaus J; Department of Dermatology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Kallenberger SM; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Stein-Thöringer CK; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.; Division Microbiome and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany., Jenzer M; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Schubert A; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; BioQuant & Department of Cell and Molecular Biology, Heidelberg University, Heidelberg, Germany.; Division Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Kahle S; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Williams A; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Hoyler B; Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany., Zielske L; NCT Liquid Biobank, National Center for Tumor Diseases (NCT), Heidelberg, Germany., Skatula R; NCT Liquid Biobank, National Center for Tumor Diseases (NCT), Heidelberg, Germany., Sawall S; Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany., Leber MF; Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Kunes RZ; Department of Statistics, Columbia University, New York, NY, USA., Krisam J; Institute of Medical Biometry, Heidelberg University, Heidelberg, Germany., Fremd C; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.; Division of Gynecological Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany., Schneeweiss A; Division of Gynecological Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany., Krauss J; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Apostolidis L; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Berger AK; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Haag GM; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Applied Tumor-Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany., Zschäbitz S; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Halama N; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.; Department of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Helmholtz Institute for Translational Oncology (HITRON), Mainz, Germany., Springfeld C; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Kirsten R; NCT Liquid Biobank, National Center for Tumor Diseases (NCT), Heidelberg, Germany., Hassel JC; Department of Dermatology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Jäger D; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Applied Tumor-Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany., Ungerechts G; Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.; CanVirex, Heidelberg, Germany.; Ottawa Hospital Research Institute, Cancer Therapeutics Program, Ottawa, Ontario, Canada. |
| Corporate Authors: | NCT ANTICIPATE Investigators |
| Source: | Nature cancer [Nat Cancer] 2022 Sep; Vol. 3 (9), pp. 1137. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
